New Year Greetings from Hampus Hillerstrom
Dear Friend of LuMind IDSC, Recently, I spoke with a family whose newborn baby had heart surgery. As many of
January 18, 2023
Dear Friend of LuMind IDSC, Recently, I spoke with a family whose newborn baby had heart surgery. As many of
On Friday, January 6, the U.S. Food & Drug Administration (FDA) granted accelerated approval for lecanemab, an anti-amyloid drug to
Our Impact Report 2022 highlights our accomplishments as an organization during a remarkable year. 2022 saw Down syndrome research receive
At an Alzheimer’s disease research conference last week, new clinical trial data was presented for an antibody drug candidate called
LuMind IDSC and the Down Syndrome Clinical Trials Network are pleased to announce the launch of the DS-CTN Data and
Eisai, a Japanese pharmaceutical company, and its partner Biogen, a Massachusetts-based biotechnology company, recently announced positive “topline” results from the
Long-COVID in adults with intellectual disability In a recent report, the National Task Group on Intellectual Disabilities and Dementia Practices
September 16, 2022 Research recently published in the journal Science (Manfredi-Lozano et al., Science 377, eabq4515 (2022)) raises the possibility
EXAMINING ADULTS WITH NEUROATYPICAL CONDITIONS FOR MCI/DEMENTIA DURING COGNITIVE IMPAIRMENT ASSESSMENTS: REPORT OF THE NEUROATYPICAL CONDITIONS EXPERT CONSULTATIVE PANEL July,
AN EXPLAINER FOR THE DOWN SYNDROME COMMUNITY April 15, 2022 BACKGROUND On April 7, 2022, the federal Centers for